Business Context and Reporting Period
This Form 8-K Current Report was filed by Aurinia Pharmaceuticals Inc. on June 14, 2021. The filing reports a corporate governance event rather than financial results for a specific fiscal period.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to director compensation:
- Annual Cash Retainer: $45,000
- Committee Retainer: $7,500 (Compensation Committee)
- Equity Grant Value: $200,000 (aggregate grant date value)
- Stock Options: 53,291 options with an exercise price of $12.86
Material Changes
The material change reported is the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Board of Directors. She was also appointed to the Compensation Committee. No changes to financial performance or operational status are reported in this document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. It strictly details the appointment and associated compensation arrangements.
Investor Verification Checklist
- Verify Dr. Balakrishnan's professional background and qualifications as a new Board member.
- Confirm the total annual cash and equity compensation package ($45,000 + $7,500 + $200,000 value).
- Review the terms of the 53,291 stock options granted (exercise price $12.86) against current market prices.
- Check the attached press release (Exhibit 99.1) for additional context on the appointment.